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Abstract Glycosynthases are nucleophile mutants of retaining
glycosidases that catalyze the glycosylation of sugar acceptors
using glycosyl fluoride donors, thereby synthesizing oligosac-
charides. The ‘original’ glycosynthase, derived from Agrobacter-
ium sp. L-glucosidase (Abg) by mutating the nucleophile
glutamate to alanine (E358A), synthesizes oligosaccharides in
yields exceeding 90% [Mackenzie, L.F., Wang, Q., Warren,
R.A.J. and Withers, S.G. (1998) J. Am. Chem. Soc. 120, 5583^
5584]. This mutant has now been re-cloned with a His6-tag into a
pET-29b(+) vector, allowing gram scale production and single
step chromatographic purification. A dramatic, 24-fold, im-
provement in synthetic rates has also been achieved by
substituting the nucleophile with serine, resulting in improved
product yields, reduced reaction times and an enhanced synthetic
repertoire. Thus poor acceptors for Abg E358A, such as PNP-
GlcNAc, are successfully glycosylated by E358S, allowing the
synthesis of PNP-L-LacNAc. The increased glycosylation
activity of Abg E358S likely originates from a stabilizing
interaction between the Ser hydroxyl group and the departing
anomeric fluorine of the K-glycosyl fluoride.
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1. Introduction
Oligosaccharides have considerable potential as therapeu-
tics but are only now slowly assuming this important role
[1^3]. One of the reasons for their slow development has
been the considerable di⁄culty in synthesizing oligosaccha-
rides on the scale necessary for their clinical evaluation. En-
zymatic synthesis has emerged as the method of choice for
such large scale syntheses, there being two major approaches.
Glycosyl transferase-catalyzed synthesis using nucleotide
phosphosugar donors is a logical choice, but one that until
recently has been limited by the availability of both enzyme
and substrates [4^7]. The alternative method involving the use
of glycosidases has a much longer history [8^11] and com-
prises two separate approaches. The equilibrium approach
relies upon the use of high concentrations of sugars to gen-
erate products, but only o¡ers very modest (typically 6 15%)
yields, and su¡ers from almost complete lack of regiochemical
control. The kinetic approach requires a retaining glycosidase
and uses a relatively reactive glycosyl donor, typically a nitro-
phenyl glycoside or a glycosyl £uoride, to maintain a steady
state concentration of the glycosyl-enzyme intermediate that is
intercepted by an added sugar moiety bound productively in
the aglycone site [12]. This approach provides better yields
(typically 10^40%) and greater regiochemical control, but still
is not generally economical for large scale syntheses.
A new variation on this approach that eliminates the hydro-
lytic reaction was introduced recently [13]. A speci¢cally mu-
tated retaining L-glycosidase is used in which the glutamic or
aspartic acid group of the catalytic nucleophile, itself readily
identi¢ed using the 2-£uorosugar strategy previously devel-
oped [14,15], is replaced by the methyl group of an alanine
residue. Such mutants are incapable of hydrolyzing oligosac-
charides, but can transfer a sugar moiety from a glycosyl
£uoride donor of the opposite anomeric stereochemistry to
that of the normal substrate. Thus the E358A mutant of
Agrobacterium sp. L-glucosidase (Abg) will transfer the glu-
cose moiety from K-glucosyl £uoride to a suitable acceptor
sugar in high (typically s 80%) yields without any hydrolysis
of product. The approach was demonstrated with several dif-
ferent glycosyl £uoride donors and a range of di¡erent accep-
tor sugars; good yields being obtained in each case. A second
example has since been published involving an endoglycanase
[16]. Although e¡ective as catalysts and producing excellent
yields, the reactions are still somewhat slow, therefore requir-
ing substantial quantities of mutant enzyme and/or extended
incubation times. This led us to search for mutants with im-
proved properties. Here, we report the generation and evalu-
ation of a mutant of Abg of signi¢cantly improved properties,
catalyzing glycoside formation with rate constants approxi-
mately 24-fold greater than those of the Ala mutant.
2. Materials and methods
2.1. Reagents, enzymes and bacterial strains
Plasmid-containing strains were grown in Luria^Bertani broth con-
taining 50 mg/ml kanamycin (LBkan) or in TYP (16 g/l tryptone, 16 g/l
yeast extract, 5 g/l NaCl, 2.5 g/l K2HPO4) containing 50 mg/ml ka-
namycin (TYPkan). Pwo DNA polymerase and deoxynucleoside tri-
phosphates were from Boehringer Mannheim. Restriction endonu-
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cleases and T4 DNA ligase were from New England BioLabs. Electro-
competent Escherichia coli Topp10 cells and the pZeroBlunt cloning
kit were from Invitrogen. The pET-29b(+) expression vector, electro-
competent E. coli BL21(DE3) cells and His-bind metal chelation resin
were from Novagen. Preparation of oligonucleotide primers and
DNA sequencing was performed at the Nucleic Acids and Peptide
Service (NAPS) Unit, University of British Columbia.
2.2. Construction of His6-tagged Abg
The gene encoding the Abg (abg) was ampli¢ed by the polymerase
chain reaction (PCR) and subsequently subcloned into the His6 fusion
protein expression vector, pET-29b(+) (Novagen). The PCR mixture
contained 10 WM oligonucleotide primers (shown below), 1 mM con-
centrations of the four deoxynucleoside triphosphates in 100 ml of
DNA polymerase bu¡er, and 25 ng of plasmid pTug10Nabg, carrying
the entire abg gene [17]. After heating the mixture to 95‡C, the reac-
tion was started by adding 5 U of Pwo DNA polymerase (Boehringer
Mannheim). Thirty PCR cycles (45 s at 94‡C, 45 s at 56‡C and 70 s at
72‡C) were performed in a thermal cycler (Perkin Elmer, GeneAmp
PCR System 2400). Agarose gel electrophoresis of the PCR product
revealed a single DNA fragment of approximately 1380 bp. The prim-
ers were as follows: 5P-AA CAT ATG GGA CCG TTA TGG CTA
GAC-3P (forward primer) and 5P-GAG AAC CTC GAG CCC CTT
GGC AAC CCC ATG GTT CC-3P (reverse primer). Underlined are
the restriction sites NdeI and XhoI introduced by the two primers. The
PCR product was puri¢ed and subsequently subcloned into the clon-
ing vector pZero2.0 as well as the expression vector pET-29b(+) using
procedures described elsewhere [18].
2.3. Construction of Abg E358S by site-directed mutagenesis
A ‘megaprimer’ PCR approach [19] was used to introduce a serine
residue at the position of the catalytic nucleophile (E358). The oligo-
nucleotide primers were as follows. Mutagenic reverse primer, 5P-TT
GTA GCA GGC GCC GTT GCT GGT GAT GTA GCA CTC
CGG-3P (the mutated codon is underlined), forward primer, 5P-
GGT CTT CAA GGG CGA ATA TCC-3P, reverse primer, 5P-TCA
CCC CTT GGC AAC CCC ATG-3P. In a ¢rst PCR, a 300 bp frag-
ment was ampli¢ed using the mutagenic and the forward primer. The
PCR product was puri¢ed and subsequently used in a second PCR as
megaprimer. The conditions for the ¢rst PCR were as described
above, but pTug10NabgE358C [20] was the template. The mixture
for the second PCR contained 2.5 Wg megaprimer, 10 mM concen-
trations of reverse primer as well as 25 ng of plasmid pTug10Nab-
gE358C. The following PCR protocol was used: 5 cycles (60 s at
95‡C, 180 s at 72‡C), then 25 cycles (45 s at 95‡C, 45 s at 58‡C and
80 s at 72‡C). The major band of about 600 bp was puri¢ed by
agarose gel electrophoresis. The puri¢ed PCR fragment was ligated
into the vector pZero2.0 and subsequently subcloned into pET29-
abgHis6. The cloned product, called pET29abgE358S, was sequenced
to verify the induced mutation. The vector pET29abgE358A was pre-
pared in a similar manner (data not shown).
2.4. Overexpression of the gene and puri¢cation of His6-tagged
Abg358S
Recombinant Abg E358S was puri¢ed from IPTG-induced cultures
of E. coli BL21(DE3) cells, carrying the plasmid pET29abgE358S. The
cell suspension was passed two times through a French press at 5‡C,
centrifuged at 10 000Ug for 30 min and the soluble cell extract puri-
¢ed by Ni2 chelation chromatography (His-bind resin, Novagen). A
20 l culture of Abg E358S processed in this way yielded 3.5 g of pure
mutant enzyme.
2.5. Rescue and transglycosylation kinetics
Rescue of the glycosidic bond cleaving activity of each nucleophile
mutant using anionic nucleophiles was performed as reported previ-
ously [21]. Concentrations of mutant enzyme solutions were quanti¢ed
directly by absorbance at 280 nm (O0:1%280 = 2.20). Curve-¢tting was per-
formed with GraFit 3.0 [22].
All transglycosylation kinetic studies were performed at 25‡C. As-
say solutions consisted of K-D-galactopyranosyl £uoride (K-GalF) and
para-nitrophenyl L-D-glucopyranoside (PNPG) in 150 mM NaPi,
150 mM NaCl, 1 mg/ml bovine serum albumin, pH 7. An Orion
£uoride electrode (model 96-09BN), interfaced with a Fischer Scien-
ti¢c Accumet 925 pH/ion meter, was used to monitor £uoride release
following addition of a small aliquot of Abg E358A or E358S. Final
concentrations of enzyme were 0.108 mg/ml (2.12 WM) E358S and
1.94 mg/ml (37.9 WM) E358A. All enzymatic rates were corrected
for the spontaneous hydrolysis rate of K-GalF. In the ¢rst studies, a
¢xed concentration of K-GalF (57 mM) was used to determine an
initial rate pro¢le for PNPG. A maximal rate was observed at 22
mM PNPG followed by substrate inhibition at higher concentrations
of PNPG (see Fig. 2a). These data were ¢t according to Eq. 1 using
GraFit.
V o  V maxS
Km  SS
2
K i
1
Ki represents the inhibition constant for the substrate (in this case
PNPG) binding in a non-productive mode. The complementary ex-
periment was carried out in which PNPG was kept at a constant
concentration of 22 mM and the concentration of K-GalF was varied
(see Fig. 2b). Apparent values of kcat, Km and kcat/Km for GalF and
PNPG were also derived using GraFit.
In studies of the dependence of reaction rate upon pH, the follow-
ing bu¡ers were used: pH 5^6, 100 mM sodium citrate; pH 7^8,
100 mM NaPi; pH 8^9, 100 mM 3-[(1,1-dimethyl-2-hydroxyethyl)-
amino]-2-hydroxypropanesulfonic acid. Apparent values of kcat/Km
for K-GalF were determined from the linear dependence of rates
(Vo = kcatEo/Km) measured at three low concentrations of K-GalF
(5, 10 and 15 mM) at a ¢xed concentration of PNPG (22 mM).
2.6. Oligosaccharide synthesis with Abg E358S
In a typical reaction, the acceptor glycoside was dissolved in ap-
proximately 2.5 ml 150 mM ammonium hydrogen carbonate (pH 7.9)
to which an aliquot of donor glycosyl £uoride (K-D-glucopyranosyl
£uoride (K-GlcF) or K-GalF) and Abg E358S, all in bu¡ered solutions
of ammonium hydrogen carbonate, were added. Acceptor concentra-
tions ranged from 20 to 40 mM, donor concentrations from 30 to
80 mM, and Abg E358S concentrations from 0.25 mg/ml (4.85 WM) to
1 mg/ml (20 WM). Reaction times ranged from 2 h to 7 days. Reac-
tions were monitored by thin layer chromatography (TLC) (silica gel
60 F254, aluminum-backed, Merck) using 7:2:1 ethyl acetate/metha-
nol/water. Plates were visualized by exposure to 10% sulfuric acid in
methanol followed by charring.
2.7. Oligosaccharide puri¢cation and characterization by electrospray
ionization mass spectrometry (ESI-MS)
Upon completion, reaction solutions were lyophilized, re-dissolved
in 1 ml water, and the mutant enzyme removed by ultra¢ltration
(Centricon-30, Amicon). Reaction products were puri¢ed by prepara-
tive high performance liquid chromatography (HPLC) on a TosoHaas
Amide-80 column (21.5 mmU30 cm, # 14460). A BioSepra ProSys
workstation (Beckman Coulter) was used to generate a linear gradient
of 80:20 to 60:40 acetonitrile/water at a £ow rate of 5 ml/min. Prod-
ucts were detected using a UV/Vis detector. Product fractions were
concentrated in vacuo then lyophilized. Reaction yields were deter-
mined by integration of the peaks within the HPLC chromatograms
using an analysis program developed by BioSepra. Molecular weights
of oligosaccharide products were con¢rmed by ESI-MS (Perkin Elmer
API 300, Sciex, Thornhill, Ont., Canada).
3. Results and discussion
While the E358A mutant of Abg successfully catalyzed the
desired oligosaccharide synthesis reaction without observable
product hydrolysis, a more e¡ective mutant with higher cata-
lytic activity was highly desirable, particularly to improve re-
activity with the ‘slower’ acceptors. Substitution of a more
polar side chain than the methyl group of alanine seemed a
reasonable aim since this should provide a more favorable
binding site for the anomeric £uoride as it departs during
the glycosyl transfer reaction. Such a side chain must be
smaller than that of the original glutamic acid to allow bind-
ing of the K-anomeric £uoride. An aspartic acid is not a useful
substitution since we had shown previously that the E358D
mutant of Abg catalyzes slow hydrolysis via the normal path-
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way [23]. Further, substitution of cysteine could cause prob-
lems since we had also shown previously that this mutant
reacts with the substrate 2,4-dinitrophenyl-L-D-glucopyrano-
side (DNPG) to generate a stable K-glucosyl cysteine adduct
that hydrolyzes only very slowly (t1=2V15 h) [20]. Substitu-
tion with serine seemed to be a good alternative since the
hydroxymethyl side chain should be su⁄ciently small to ac-
commodate the axial £uorine and might even hydrogen bond
to the departing £uoride (Fig. 1). Moreover, its alcohol moi-
ety should be considerably less nucleophilic than the thiol of
cysteine, thus unwanted adduct formation should be less
likely.
Therefore, the E358S mutant of Abg was generated by side-
directed mutagenesis by a ‘megaprimer’ PCR method using
three oligonucleotide primers, one of which carried the muta-
tion. The product of the ¢rst PCR reaction served, after pu-
ri¢cation, as a primer in the second PCR reaction (mega-
primer). High megaprimer concentration is the critical factor
in this approach [19]. A 295 bp gene fragment, carrying the
mutation, was exchanged with the corresponding fragment in
the wild-type (wt) gene. This procedure minimized the possi-
bility of other mutations arising during the gene ampli¢cation
by PCR.
Although systems were constructed for production in E. coli
of Abg wt, and the E358A and E358C mutants, and high
yields were obtained, puri¢cation remained a relatively
lengthy process [24]. Therefore, wt Abg and the mutants
E358S, E358A and E358C were produced as His6-tagged-fu-
sions, after subcloning the genes into an appropriate vector.
Puri¢cation was achieved in a single step on the His-bind
resin; 150^250 mg of each enzyme was obtained from a 1 l
culture. The enzyme preparations were judged to be pure by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
silver staining. A large scale preparation of Abg E358S from a
20 l culture yielded 3.5 g of puri¢ed protein (data not shown).
The His6-tagged Abg E358S and E358A were assayed with
the highly reactive substrate DNPG and were found to be
completely devoid of glycosidic bond cleaving activity, as ex-
pected [21]. However, signi¢cant activity was recovered in the
presence of 2 M azide (kcat/Km = 33.9 min31 mM31 for
E358A, 9.62 min31 mM31 for E358S) or 5 M formate (kcat/
Km = 1616 min31 mM31 for E358A, 900 min31 mM31 for
E358S). This rescue occurs by a mechanism in which the
anion attacks directly at the anomeric center from the K-
face, in place of the catalytic nucleophile, thereby cleaving
the substrate with net inversion of con¢guration to give an
K-glycosyl azide (or formate) product. Such behavior is a
standard feature of retaining glycosidase nucleophile mutants
as reported by this group [21,25] and others [26,27]. Of note
here is the signi¢cantly lower activity of the serine mutant
with azide or formate relative to the alanine mutant, which
may well re£ect the greater steric bulk of the serine side chain.
No activity was detected with either mutant in the presence of
molar concentrations of sodium acetate, indicating that only
small nucleophiles can access a catalytically active position in
the active site when DNPG is bound.
Abg E358S proved to be an e¡ective glycosynthase when
presented with K-glucosyl or K-galactosyl £uoride donors and
a variety of acceptors (Tables 1 and 2). The kinetics of gly-
cosylation of PNPG with K-GalF using E358S or the ‘origi-
nal’ glycosynthase, E358A, were compared using a £uoride
electrode to monitor £uoride release. Because transfer to an
acceptor with an axial 4-hydroxyl group is not observed with
either E358S or E358A, the use of K-GalF as donor for ki-
netic studies ensured that the observed release of £uoride cor-
responded to a single galactosyl transfer, the product itself
being a poor acceptor. Indeed, TLC analysis of assay mixtures
indicated the formation of a single disaccharide product.
Higher concentrations of PNPG at a ¢xed concentration of
K-GalF inhibited transglycosylation by E358S (Fig. 2a), indi-
cating that the acceptor can adopt a non-productive binding
mode at high concentrations. An apparent Km of 22 þ 5 mM
and an apparent Ki of 16 þ 4 mM, respectively, were obtained
from a ¢t of the data in Fig. 2a with Eq. 1. Considering that
PNPG is an excellent substrate for the Abg wt (kcat = 169 s31,
Km = 78 WM) [24], this type of inhibition is not unexpected
because PNPG can be envisioned to bind readily to the 31
subsite in the mutant enzyme and prevent binding of the do-
nor galactosyl £uoride in a productive mode. Variation of the
Fig. 1. Mechanism for Abg E358S acting as a glycosynthase.
Fig. 2. Transglycosylation kinetics with Abg E358S. (a) Variation of
PNPG with K-GalF ¢xed at 57 mM. The curve shown is a ¢t of
the data according to Eq. 1. (b) A comparison of the transglycosy-
lation kinetics of Abg E358S (b) and Abg E358A (a). PNPG is the
acceptor in both cases, ¢xed at 22 mM.
Table 1
Abg E358S transglycosylation reactions using K-GalF as donor
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K-GalF concentration at a ¢xed concentration of PNPG
(22 mM) a¡orded standard saturation kinetics for E358S
(Fig. 2b) with apparent kinetic parameters of Km = 220 þ 12
mM, kcat = 177 min31 and kcat/Km = 0.800 min31 mM31. By
contrast, saturation with K-GalF ([PNPG] = 22 mM) was not
observed with E358A (Fig. 2b). The data gave a value of
0.0338 min31 mM31 for kcat/Km, a value that is 24-fold less
than the corresponding rate constant for E358S. The signi¢-
cantly higher activity of the Ser mutant, together with the
obtaining of a measurable Km for K-GalF with E358S but
not with E358A, suggest that a speci¢c interaction is formed
between the Ser side chain and GalF, most likely through a
hydrogen bond to the anomeric £uorine (Fig. 1). Although
OH^£uorine hydrogen bonds are known to be weak at best in
£uorocarbons, an OH^£uoride hydrogen bond will be consid-
erably stronger [28]. Thus the hydrogen bond from serine
would facilitate stabilization of the glycosylation transition
state by neutralizing developing negative charge on the de-
parting £uoride.
The pH dependence of the transglycosylation reaction was
also examined for E358S and E358A (Fig. 3). No signi¢cant
e¡ect on (kcat/Km)app: was observed for either mutant over a
range of pH 9^5. Although one might have expected a titra-
tion corresponding to the acid/base catalyst E170, this pro¢le
is analogous to the very broad pH rate pro¢le observed for
the wt Abg [24].
The synthetic utility of Abg E358S was investigated using
K-GlcF or K-GalF as donors to various acceptors (Tables 1
and 2). The yields of oligosaccharides (determined by HPLC,
with masses con¢rmed by ESI-MS) were better than reported
previously for E358A [13]. An increased rate of glycosylation
is expected to improve yields as a result of less of the donor
glycosyl £uoride being lost to spontaneous hydrolysis. It is
also signi¢cant that glycosides such as PNP-GlcNAc that
are weak acceptors for E358A were glycosylated by E358S
to form, in this example, para-nitrophenyl L-N-acetyllactos-
amine (PNP-LacNAc), a valuable precursor to various cell
surface antigens, in a reasonable yield of 63% (Table 1, entry
4). Such syntheses could easily be done on a large scale since
the E358S mutant can be produced in gram quantities.
It has been demonstrated that the glycosylation rates of the
glycosynthase Abg E358A are improved considerably by sub-
stitution of the nucleophile with serine (E358S) rather than
alanine. Although this mutation reduces the free space be-
tween the anomeric carbon of a substrate and the serine hy-
droxyl group relative to the alanine methyl (as indicated by
rescue studies with anionic nucleophiles), a favorable interac-
tion with the anomeric £uorine of a glycosyl £uoride may
occur in the ground state, and more strongly in the glycosy-
lation transition state, resulting in enhanced catalysis. Presum-
ably a similar mutation in other retaining glycosidases should
enhance their glycosynthase activity, or even elicit such activ-
ity where the corresponding alanine mutation had failed,
thereby extending the glycosynthase methodology. Likewise,
as demonstrated by Abg E358S, the synthetic repertoire of
existing glycosynthases may be broadened as a result of great-
er glycosylation activity.
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